Director of Natera, Sells Over Half a Million Shares of Stock
December 26, 2023
☀️Trending News
Natera ($NASDAQ:NTRA), Inc., a leading provider of comprehensive genetic testing and diagnostics, recently saw one of its directors dispose of 644000 shares of stock through insider selling. Natera, Inc. is a publicly traded company whose primary focus is on genetic testing and diagnostics. It offers products and services to its customers in the areas of reproductive health, oncology and organ transplantation. The director of Natera who recently sold the shares of stock is Mark A. Seamans. He disposed of over half a million shares, which represents a substantial portion of his holdings in the company.
This insider selling has raised some questions from investors, as it is uncommon to see such a large transaction in a single day. Overall, it appears that Mark A. Seamans is taking a cautious approach with his investments in Natera. While this sale of stock may have been for personal reasons, it is important for investors to understand the potential implications of such a large transaction.
Stock Price
This caused the stock to open at $60.3 and closed at $60.8, up 0.9% from the previous close of $60.3. This represents a significant transaction for the company, as it is the first time that the director has sold such a high number of shares in one transaction. It is unclear what this sale could mean for the future prospects of the company, but investors will be keeping a close eye on Natera‘s stock price to see if any further changes occur. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Natera. More…
| Total Revenues | Net Income | Net Margin |
| 988.72 | -499.34 | -50.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Natera. More…
| Operations | Investing | Financing |
| -269.96 | 165.75 | 715.79 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Natera. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.45k | 661.86 | 6.59 |
Key Ratios Snapshot
Some of the financial key ratios for Natera are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 39.8% | – | -49.2% |
| FCF Margin | ROE | ROA |
| -31.5% | -44.1% | -21.0% |
Analysis
At GoodWhale, we believe analyzing NATERA‘s fundamentals is key to making informed investment decisions. After examining the company’s cash flows and debt, we give NATERA an intermediate health score of 4/10. This suggests that NATERA may be able to pay off debt and fund future operations. We classify NATERA as a ‘cheetah’ company. This type of company is characterized by high revenue or earnings growth, but is considered less stable due to lower profitability. Investors who are willing to take on higher risks- such as venture capitalists, angel investors, and growth investors- may be interested in this type of company. In terms of performance metrics, NATERA is strong in asset growth and weak in dividend and profitability. We suggest investors examine these metrics and others closely to determine if NATERA is an appropriate investment for their portfolio. More…
Peers
The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera‘s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.
– Genetic Technologies Ltd ($ASX:GTG)
Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.
Summary
Investors should thoroughly analyze the implications of this insider selling before making any decisions. Factors to consider include the director’s current financial situation, the company’s current financial position and fundamentals, any potential future developments, and market sentiment. Overall, investors should use caution when considering investing in Natera at this time and perform further research to make an informed decision.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
